RxDoctor Payments DataLook up a doctor →

Ali Moghani Lankarani, MD

Gastroenterology · Jacksonville, FLNPI 1215079256

Payments from drug & device makers

$713,261in general payments, 2019–2025

Across 577 payments — averaging $1236.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$579K
  • Olympus Corporation Of The Americas$49K
  • Regeneron$38K
  • Micro-tech Endoscopy USA, Inc.$10K
  • Covidien LP$10K
  • Olympus America Inc.$9K
  • plus $18K from 36 others

What the payments were for

  • Consulting fees$27,19026%
  • Speaking & faculty fees$14,89514%
  • Travel & lodging$4,5134%
  • Food & beverage$12,84112%
  • Education$45,95344%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$713,261 in reported general payments places this provider in the 95th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida

Medicare billing

Part B allowed, 2024
$197,081
Medicare patients
628
Services billed
1,548

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase13$48,826
LinzessLinaclotide29$28,585
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates54$3,416
ClenpiqSod Picosulf/Mag Ox/Citric Ac18$3,098
Omeprazole119$1,999
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl59$867
Ondansetron HclOndansetron Hcl/Pf17$681
Pantoprazole Sodium42$406
Famotidine11$215
Gabapentin12$148
Levofloxacin20$42
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav12$40
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen11$40

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$2,141$77,41142 claims
Ferring Pharmaceuticals Inc.Clenpiq$26$3,09818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,388 gastroenterology providers in Florida.

Other gastroenterology in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →